SAN DIEGO – August 14, 2019 – NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced a milestone of 10,000 implants of the Precice® system for conditions related to limb lengthening and reconstruction from NuVasive Specialized Orthopedics™. The Precice system is an internal nail that once implanted, utilizes an External Remote Controller (ERC) to non-invasively lengthen the limb.
“Precice has completely changed the game in limb lengthening and reconstruction surgery and is rapidly becoming the gold standard of care for patients with conditions related to limb-length discrepancy,” said Stuart Green, MD, orthopedic surgeon at UC Irvine School of Medicine. “Before Precice, patients were limited to bulky, painful external fixation devices that significantly impacted their mobility and comfort. We have seen a huge paradigm shift in the last few years with the adoption of Precice, due to the reliability of the External Remote Control, the precision of lengthening and compression, patient comfort, the dramatic reduction of infections and the elimination of disfiguring scars when compared with external skeletal fixators.”
The Precice system is a state-of-the-art device designed to eliminate the need for external fixation devices or shortening of the healthy limb, both of which were previously considered the gold standard of care for patients with a limb length discrepancy. An intramedullary nail is implanted into the patient’s femur, tibia or humerus, and is remotely controlled through a complex internal gear system. Physicians personalize treatment based on the individual needs of the patient by programming the ERC to perform customizable lengthening until prescribed correction is achieved. Once programmed, patients utilize the remote for just seven minutes per day, and can achieve up to 80mm of limb lengthening throughout the treatment from the comfort of their own home.
“With over 10,000 devices implanted and more than 30 peer-reviewed clinical studies published since its commercial release in 2011, Precice has proven to be a validated and preferred approach to addressing limb length discrepancies by surgeons and patients alike,” said Massimo Calafiore, president of NuVasive Specialized Orthopedics. “This milestone underscores NuVasive’s commitment to innovate with the mission of transforming the current standards of orthopedic care.”
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With more than $1 billion in revenues, NuVasive has approximately 2,600 employees and operates in more than 50 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.